This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Cancer Supportive Care Products Market

Market Insights on Cancer Supportive Care Products covering sales outlook, demand forecast & up-to-date key trends

Cancer Supportive Care Products Market By Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Compounding Pharmacies) & Region - Forecast to 2020-2030

Cancer Supportive Care Products Market Outlook & Key Findings

  • Cancer supportive care products market is expected to grow at about 4% y-o-y in 2020
  • Erythropoietin stimulating agents to hold leading revenue share, given their efficacy in treating chemotherapy-induced anemia
  • Sales of cancer supportive care products via hospital pharmacies to remain prominent through 2030
  • Usage of cancer supportive care products in treating leukemia to accelerate in the coming years
  • North America to spearhead the global cancer supportive care products market over the following decade
Customize this Report

Let us know your requirement to get
100% FREE customization

Cancer Supportive Care Products Market Analysis

Growing prevalence of cancer has consistently spurred the demand for cancer treatments such as chemotherapy over the past decade. That said, radiation therapy comes with several side effects that are challenging for cancer patients to confront, while they undergo the course of procedure.

While cancer treatment is significantly progressing, rising incidences of side effects are growing as well that are addressed by cancer supportive care products.

Oncology is among the fastest-growing therapeutic areas (TAs) worldwide, and is projected to capture about 26% of pharmaceutical sales by 2022, with 107 novel drug approvals in 2018 alone.

In addition, the domain is highly competitive – 35% of the industry preclinical pipeline lies in oncology, and leading players have a commercial footprint. This investment and interest is partially driven by rapid development cycles.

Technological intervention in cancer supportive care products has enabled to treat various indications following chemotherapy procedure, as well as chemotherapy-induced nausea, vomiting, anemia, and neutropenia.

The global cancer supportive care products market is currently growing at a sound pace and is expected to experience moderate growth over the forecast period, 2020-2030.

Cancer Supportive Care Products Market Trends – The Biosimilar Solution to Expensive Cancer Treatment

Biosimilar drugs (or biosimilars), used in management of several disease conditions, account for about 25% of global pharmaceutical industry.

Adoption of biosimilar drugs among patients having cancer has triggered significant advancements in cancer treatments and supportive care.

The US FDA has approved various biosimilars for treatment of cancer and supportive care management, and the figure is expected to follow a positive trend.

Further, usage of biosimilars is associated with exponential cost-savings. Recent studies stress that biosimilars will result in a reduction of US$ 54 Bn in direct expenditure on biologic drugs over 2017-2026, or around 3% of overall anticipated biologic spending within the same timeframe, ranging of US $24-150 Bn.

Prominent drivers of cost savings include number and timing of biosimilars in development and marketing, acceptability of usage among prescribers and patients, cost of biosimilar development, changes in global market size, cost-sharing, payer coverage, and other regulatory policies.

Although these figures appear promising, the expected cost savings with usage of biosimilars are projected to remain modest.

Globally, the cost of biosimilars is about 20-30% less compared to that of reference drugs. The cost savings will bank on several factors such as cost of reference drugs, their sales, and degree of competition.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Hospital Pharmacies to Remain Leading Value Creator

Among the distribution channels, hospital pharmacies are expected to generate greater total return to shareholders (TRS) – over 50% of overall cancer supportive care products market revenue.

About 33% of overall healthcare companies are looking forward to transmuting their whole business model in 2020, with hospitals, the major providers of cancer care, accounting for 66% of them.

Pharmacy is an ever-evolving landscape, as such, hospital pharmacies are striving to keep pace with surging demand for cancer supportive care products and consistent rise in healthcare expenses. With inbound costs of oncology drugs, hospital pharmacies are in a constant juggle to reduce expenses and keep the budget on track.

Hospital pharmacies are monitoring trends on cancer supportive care products that have measurable effect on pharmacy budget in order to ensure maximum savings for hospitals’ pharmaceutical expenses.

While hospital pharmacies continue to capture a bigger slice of cancer supportive care products market value, players are also unlocking new revenue lines in retail pharmacies.

Cancer Supportive Care Products Market Regional Analysis – North America Leads, APAC’s Market to Speed up

Regionally, North America continues to engage manufacturers of cancer supportive care products over the following decade. Cancer is the major cause of mortality in Canada and the second-leading cause, after cardiovascular diseases (CVD), in the US.

  • Around 1.9 million new incidences of cancer and 693,000 cancer mortalities were reported in Northern America in 2018.
  • The most prevalently diagnosed cancers are prostate and breast cancer, while lung cancer remains the leading cause of mortality in the region.

Consequently, governments in the US and Canada are substantially investing in cancer research and development of pharmaceutical drugs, especially erythropoietin stimulating agents, and granulocyte colony stimulating factors.

Moreover, the regulatory authorities have been showing immediacy in approving various cancer supportive care products. The US has granted approval to around 23 biosimilars by July 2019, of which 14 carry indications for use in oncology.

Cancer Supportive Care Products Market Download Report Brochure

In a similar vein, Asia Pacific (APAC) is also offering value-capture opportunities for players in of cancer supportive care products market.

Studies reveal that nearly half of the global cancer cases are reported in APAC, and by 2030, the number of individuals fighting cancer is likely to soar by about 35%, with mortality increasing by about 40%.

Biopharmaceutical companies in APAC are beginning to launch APAC-centric clinical therapeutics research. Within oncology domain, major portion of APAC drug development is centered on breast, lung, and colorectal cancers. Carrying an enormous cancer burden, the oncology drug market in China is expected to hit US$ 18 Bn by 2023.

Driven by expanding healthcare needs in tandem with supportive government policies. APAC represents tremendous opportunity for cancer supportive care product manufacturers. Countries are implementing steps to set up domestic environments that can leverage local talent and fetch foreign investment.

Cancer Supportive Care Products Market Players – Product Innovations and Launches to Shape Stakeholders’ Tactics

The cancer supportive care products market is witnessing the penetration of emerging players both at local and international level. The rising level of market competition is making new product launches, innovative applications, and tech-enabled developments a key priority among market players. Some of these include,

  • Amgen Inc. develops and delivers innovative human therapeutics – Neulasta - a PEGylated form of human granulocyte CSF.
  • Baxter International Inc. offers products under the business categories - Medication Delivery, Renal Care, and Pharmaceuticals. The company develops REGLAN Injection, which is a metoclopramide injection.
  • Bayer AG works under several business segments - Crop science, Pharmaceuticals, Animal health, and Consumer health. The company develops Xarelto, which incorporates rivaroxaban.
  • Daiichi Sankyo Co. Ltd. provides products under Pharmaceutical operation business unit. The company develops Naruvein Injection - a hydromorphone hydrochloride injection.
  • GlaxoSmithKline Plc delivers products under business segments – Vaccines, Pharmaceuticals, and Consumer healthcare. The company develops REZONIC - a neurokinin 1 receptor antagonist.
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Cancer Supportive Care Products Market Future Outlook – Cannabis-based Products to Emerge as Potential Oncological Wonder

Recent medical studies are underway unleashing the potential of cannabis or cannabidiol (CBD) in cancer treatment. With limited number of opportunities for cancer treatment currently, CBD is likely to hold great promise for both patients and scientists in addressing the situation.  

Given its cytotoxic, antiemetic, and anti-inflammatory effects, CBD has been garnering huge attention to its possible usage as a potent anti-cancer agent.

While regulatory bodies in the US have prohibited cannabis consumption, several states in the US, as well as some countries across the globe have legalized cannabis consumption for medical applications.

Two CBD drugs have been approved by the US Food and Drug Administration (FDA) - nabilone and dronabinol were researched as potent antiemetic medications.

Research and trials are in progress, incorporating swathes of scientists worldwide scrutinizing the potential of CBD for cancer treatment. However, these studies are yet to discover ample concrete scientific evidence to prove the safety and efficacy of CBD oil in treating cancer.

These scientific studies and research have been performed using animals or cancer cells developed in the laboratories. Human beings are more complex compared to animals, as such, results elaborated after the studies might not work as effectively for humans as they did in animal trials.

At present, the loopholes in research studies regarding consumption of CBD oil are creating hindrance for its approval as a potential medication for cancer treatment

Key Segment

Drug Class

  • Nonsteroidal Anti- Inflammatory Drugs
  • Anti-Infective
  • Anti-Emetics
  • Monoclonal Antibodies
  • Erythropoietin Stimulating Agents
  • Opioid Analgesics
  • Bisphosphonates
  • Granulocyte Colony Stimulating Factor

Indication

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Bladder Cancer
  • Leukemia
  • Ovarian Cancer
  • Melanoma
  • Others

Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Compounding Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

The cancer supportive care products market is likely to secure a CAGR of 2.5% through 2032.

The cancer supportive care products market size is estimated to cross US$ 26.41 Bn by 2032.

The cancer supportive care products market is likely to record a value of US$ 20.63 Bn in 2022.

North America is likely to lead the cancer supportive care products market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Market Trends

    3.2. Key Product/Development Trends

4. Key Success Factors

    4.1. Parent Market Overview

    4.2. PEST

    4.3. Regulations

    4.4. Key Promotional Strategies, By Key Manufacturers

5. Global Market Demand (in Volume) Analysis 2015-2019 and Forecast, 2020-2030

    5.1. Historical Market Volume Analysis, 2015-2019

    5.2. Current and Future Market Volume Projections, 2020-2030

    5.3. Y-o-Y Growth Trend Analysis

6. Global Market - Pricing Analysis

    6.1. Regional Pricing Analysis By Drug Class

    6.2. Pricing Break-up

        6.2.1. Manufacturer Level Pricing

        6.2.2. Distributor Level Pricing

    6.3. Global Average Pricing Analysis Benchmark

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2015–2019 and Forecast, 2020–2030

    7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

    7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Market Background

    8.1. Macro-Economic Factors

        8.1.1. Global GDP Growth Outlook

        8.1.2. Global Healthcare Expenditure Outlook

    8.2. Forecast Factors - Relevance & Impact

        8.2.1. Average Product Cost of Cancer Supportive Care Products

        8.2.2. Frequency of Product Launches

        8.2.3. Per Patient Spending

        8.2.4. Product Awareness

        8.2.5. Regulatory Approval Timeline

    8.3. Value Chain

    8.4. Market Dynamics

        8.4.1. Drivers

        8.4.2. Restraints

        8.4.3. Opportunity Analysis

9. COVID19 Crisis Analysis

    9.1. Current COVID19 Statistics and Probable Future Impact

    9.2. Current GDP Projection and Probable Impact

    9.3. Current Economic Projection as compared to 2008 Economic analysis

    9.4. COVID19 and Impact Analysis

        9.4.1. Revenue By Drug Class

        9.4.2. Revenue By Country

    9.5. 2020 Market Scenario

    9.6. Quarter by Quarter Forecast

    9.7. Projected recovery Quarter

    9.8. Recovery Scenario – Short term, Midterm and Long Term Impact

10. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Drug Class

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) and Volume Analysis By Drug Class , 2015 - 2019

    10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Drug Class, 2020 - 2030

        10.3.1. Nonsteroidal Anti- Inflammatory Drugs

        10.3.2. Anti-Infective

        10.3.3. Anti-Emetics

        10.3.4. Monoclonal Antibodies

        10.3.5. Erythropoietin Stimulating Agents

        10.3.6. Opioid Analgesics

        10.3.7. Bisphosphonates

        10.3.8. Granulocyte Colony Stimulating Factor

    10.4. Market Attractiveness Analysis By Drug Class

11. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Indication

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015 - 2019

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020 - 2030

        11.3.1. Lung Cancer

        11.3.2. Breast Cancer

        11.3.3. Prostate Cancer

        11.3.4. Liver Cancer

        11.3.5. Bladder Cancer

        11.3.6. Leukemia

        11.3.7. Ovarian Cancer

        11.3.8. Melanoma

        11.3.9. Others

    11.4. Market Attractiveness Analysis By Indication

12. Global Market Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel , 2015 - 2019

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 - 2030

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Compounding Pharmacies

    12.4. Market Attractiveness Analysis By Distribution Channel

13. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Region

    13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2019

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. East Asia

        13.3.5. South Asia

        13.3.6. Oceania

        13.3.7. Middle East and Africa

    13.4. Market Attractiveness Analysis By Region

14. North America Market Analysis 2015-2019 and Forecast 2020-2030

    14.1. Introduction

    14.2. Regional Dynamics

    14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

    14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        14.4.1.  By Country

            14.4.1.1. U.S.

            14.4.1.2. Canada

        14.4.2. By Drug Class

        14.4.3. By Indication

        14.4.4. By Distribution Channel

    14.5. Market Attractiveness Analysis

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

15. Latin America Market Analysis 2015-2019 and Forecast 2020-2030

    15.1. Introduction

    15.2. Regional Dynamics

    15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

    15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        15.4.1.  By Country

            15.4.1.1. Brazil

            15.4.1.2. Mexico

            15.4.1.3. Rest of Latin America

        15.4.2. By Drug Class

        15.4.3. By Indication

        15.4.4. By Distribution Channel

    15.5. Market Attractiveness Analysis

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

16. Europe Market Analysis 2015-2019 and Forecast 2020-2030

    16.1. Introduction

    16.2. Regional Dynamics

    16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

    16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        16.4.1.  By Country

            16.4.1.1. Germany

            16.4.1.2. Italy

            16.4.1.3. France

            16.4.1.4. U.K.

            16.4.1.5. Spain

            16.4.1.6. Russia

            16.4.1.7. Rest of Europe

        16.4.2. By Drug Class

        16.4.3. By Indication

        16.4.4. By Distribution Channel

    16.5. Market Attractiveness Analysis

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

17. South Asia Market Analysis 2015-2019 and Forecast 2020-2030

    17.1. Introduction

    17.2. Regional Dynamics

    17.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

    17.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        17.4.1.  By Country

            17.4.1.1. India

            17.4.1.2. Malaysia

            17.4.1.3. Indonesia

            17.4.1.4. Thailand

            17.4.1.5. Rest of South Asia

        17.4.2. By Drug Class

        17.4.3. By Indication

        17.4.4. By Distribution Channel

    17.5. Market Attractiveness Analysis

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

18. East Asia Market Analysis 2015-2019 and Forecast 2020-2030

    18.1. Introduction

    18.2. Regional Dynamics

    18.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

    18.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        18.4.1.  By Country

            18.4.1.1. China

            18.4.1.2. Japan

            18.4.1.3. South Korea

        18.4.2. By Drug Class

        18.4.3. By Indication

        18.4.4. By Distribution Channel

    18.5. Market Attractiveness Analysis

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

19. Oceania Market Analysis 2015-2019 and Forecast 2020-2030

    19.1. Introduction

    19.2. Regional Dynamics

    19.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

    19.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        19.4.1.  By Country

            19.4.1.1. Australia

            19.4.1.2. New Zealand

        19.4.2. By Drug Class

        19.4.3. By Indication

        19.4.4. By Distribution Channel

    19.5. Market Attractiveness Analysis

    19.6. Key Market Participants - Intensity Mapping

    19.7. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Market Analysis 2015-2019 and Forecast 2020-2030

    20.1. Introduction

    20.2. Regional Dynamics

    20.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019

    20.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030

        20.4.1.  By Country

            20.4.1.1. GCC Countries

            20.4.1.2. South Africa

            20.4.1.3. Rest of Middle East and Africa

        20.4.2. By Drug Class

        20.4.3. By Indication

        20.4.4. By Distribution Channel

    20.5. Market Attractiveness Analysis

    20.6. Key Market Participants - Intensity Mapping

    20.7. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Market Analysis 2015-2019 and Forecast 2020-2030

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. Market Analysis

        21.2.1. By Drug Class

        21.2.2. By Indication

        21.2.3. By Distribution Channel

    21.3. Canada Market Analysis

        21.3.1. By Drug Class

        21.3.2. By Indication

        21.3.3. By Distribution Channel

    21.4. Mexico Market Analysis

        21.4.1. By Drug Class

        21.4.2. By Indication

        21.4.3. By Distribution Channel

    21.5. Brazil Market Analysis

        21.5.1. By Drug Class

        21.5.2. By Indication

        21.5.3. By Distribution Channel

    21.6. U.K. Market Analysis

        21.6.1. By Drug Class

        21.6.2. By Indication

        21.6.3. By Distribution Channel

    21.7. Germany Market Analysis

        21.7.1. By Drug Class

        21.7.2. By Indication

        21.7.3. By Distribution Channel

    21.8. France Market Analysis

        21.8.1. By Drug Class

        21.8.2. By Indication

        21.8.3. By Distribution Channel

    21.9. Italy Market Analysis

        21.9.1. By Drug Class

        21.9.2. By Indication

        21.9.3. By Distribution Channel

    21.10. Spain Market Analysis

        21.10.1. By Drug Class

        21.10.2. By Indication

        21.10.3. By Distribution Channel

    21.11. Russia Market Analysis

        21.11.1. By Drug Class

        21.11.2. By Indication

        21.11.3. By Distribution Channel

    21.12. China Market Analysis

        21.12.1. By Drug Class

        21.12.2. By Indication

        21.12.3. By Distribution Channel

    21.13. Japan Market Analysis

        21.13.1. By Drug Class

        21.13.2. By Indication

        21.13.3. By Distribution Channel

    21.14. South Korea Market Analysis

        21.14.1. By Drug Class

        21.14.2. By Indication

        21.14.3. By Distribution Channel

    21.15. India Market Analysis

        21.15.1. By Drug Class

        21.15.2. By Indication

        21.15.3. By Distribution Channel

    21.16. Thailand Market Analysis

        21.16.1. By Drug Class

        21.16.2. By Indication

        21.16.3. By Distribution Channel

    21.17. Indonesia Market Analysis

        21.17.1. By Drug Class

        21.17.2. By Indication

        21.17.3. By Distribution Channel

    21.18. Malaysia Market Analysis

        21.18.1. By Drug Class

        21.18.2. By Indication

        21.18.3. By Distribution Channel

    21.19. Australia Market Analysis

        21.19.1. By Drug Class

        21.19.2. By Indication

        21.19.3. By Distribution Channel

    21.20. New Zealand Market Analysis

        21.20.1. By Drug Class

        21.20.2. By Indication

        21.20.3. By Distribution Channel

    21.21. GCC Countries Market Analysis

        21.21.1. By Drug Class

        21.21.2. By Indication

        21.21.3. By Distribution Channel

    21.22. South Africa Market Analysis

        21.22.1. By Drug Class

        21.22.2. By Indication

        21.22.3. By Distribution Channel

22. Market Structure Analysis

    22.1. Market Analysis by Tier of Companies (Cancer Supportive Care Products)

    22.2. Market Concentration

    22.3. Market Share Analysis of Top Players

    22.4. Market Presence Analysis

        22.4.1. By Regional Footprint of Players

        22.4.2. Product Footprint by Players

        22.4.3. Channel Footprint by Players

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Pricing Analysis by Competition

    23.3. Competition Benchmarking

    23.4. Competition Deep Dive

        23.4.1. Amgen, Inc.

            23.4.1.1. Overview

            23.4.1.2. Product Portfolio

            23.4.1.3. Sales Footprint

            23.4.1.4. Analyst commentary

        23.4.2. Johnson & Johnson Private Limited

            23.4.2.1. Overview

            23.4.2.2. Product Portfolio

            23.4.2.3. Sales Footprint

            23.4.2.4. Analyst commentary

        23.4.3. Baxter

            23.4.3.1. Overview

            23.4.3.2. Product Portfolio

            23.4.3.3. Sales Footprint

            23.4.3.4. Analyst commentary

        23.4.4. Merck

            23.4.4.1. Overview

            23.4.4.2. Product Portfolio

            23.4.4.3. Sales Footprint

            23.4.4.4. Analyst commentary

        23.4.5. Heron Pharma

            23.4.5.1. Overview

            23.4.5.2. Product Portfolio

            23.4.5.3. Sales Footprint

            23.4.5.4. Analyst commentary

        23.4.6. Tesaro

            23.4.6.1. Overview

            23.4.6.2. Product Portfolio

            23.4.6.3. Sales Footprint

            23.4.6.4. Analyst commentary

        23.4.7. Enlivity Corporation

            23.4.7.1. Overview

            23.4.7.2. Product Portfolio

            23.4.7.3. Sales Footprint

            23.4.7.4. Analyst commentary

        23.4.8. AmerisourceBergen Corporation (ASD Healthcare)

            23.4.8.1. Overview

            23.4.8.2. Product Portfolio

            23.4.8.3. Sales Footprint

            23.4.8.4. Analyst commentary

        23.4.9.   Veru, Inc.

            23.4.9.1. Overview

            23.4.9.2. Product Portfolio

            23.4.9.3. Sales Footprint

            23.4.9.4. Analyst commentary

        23.4.10. ARIAD Pharmaceuticals, Inc.

            23.4.10.1. Overview

            23.4.10.2. Product Portfolio

            23.4.10.3. Sales Footprint

            23.4.10.4. Analyst commentary

        23.4.11. Bendalis GmbH

            23.4.11.1. Overview

            23.4.11.2. Product Portfolio

            23.4.11.3. Sales Footprint

            23.4.11.4. Analyst commentary

        23.4.12. Helsinn Healthcare

            23.4.12.1. Overview

            23.4.12.2. Product Portfolio

            23.4.12.3. Sales Footprint

            23.4.12.4. Analyst commentary

        23.4.13. Novartis AG

            23.4.13.1. Overview

            23.4.13.2. Product Portfolio

            23.4.13.3. Sales Footprint

            23.4.13.4. Analyst commentary

        23.4.14. Hoffmann-La Roche Ltd

            23.4.14.1. Overview

            23.4.14.2. Product Portfolio

            23.4.14.3. Sales Footprint

            23.4.14.4. Analyst commentary

        23.4.15. Fagron

            23.4.15.1. Overview

            23.4.15.2. Product Portfolio

            23.4.15.3. Sales Footprint

            23.4.15.4. Analyst commentary

        23.4.16. Teva Pharmaceutical Industries Ltd.

            23.4.16.1. Overview

            23.4.16.2. Product Portfolio

            23.4.16.3. Sales Footprint

            23.4.16.4. Analyst commentary

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 02: Global Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 03: Global Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 04: North America Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 05: North America Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 06: North America Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 07: Latin America Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 08: Latin America Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 09: Latin America Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 10: Europe Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 11: Europe Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 12: Europe Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 13: APAC Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 14: APAC Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 15: APAC Market Value By Distribution Channel, 2020–2030(US$ Mn)

Table 16: MEA Market Value By Drug Classes, 2020–2030(US$ Mn)

Table 17: MEA Market Value By Disease Indication, 2020–2030(US$ Mn)

Table 18: MEA Market Value By Distribution Channel, 2020–2030(US$ Mn)

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Oncology Drug Market Value (US$ Mn) 2020–2030

Figure 02: Global Cancer Supportive Care Drug Market – Scenario Forecast, 2020–2030(US$ Mn)

Figure 03: Global Market Value & Y-o-Y Growth (%), 2020–2030

Figure 04: Global Market Absolute $ Opportunity, 2020–2030

Figure 05: Global Market Y-o-Y Growth Comparison By Drug Classes, 2020–2030

Figure 06: Market Value Share & BPS Analysis By Drug Classes, 2020 & 2030

Figure 07: Global Market Value & Y-o-Y Growth (%) By Nonsteroidal Anti-inflammatory Drugs, 2020–2030

Figure 08: Global Market Absolute $ Opportunity By Nonsteroidal Anti-inflammatory Drugs, 2020–2030

Figure 09: Global Market Value & Y-o-Y Growth (%) By Anti-infective, 2020–2030

Figure 10: Global Market Absolute $ Opportunity By Anti-infective, 2020–2030

Figure 11: Global Market Value & Y-o-Y Growth (%) By Anti-emetics, 2020–2030

Figure 12: Global Market Absolute $ Opportunity By Anti-emetics, 2020–2030

Figure 13: Global Market Value & Y-o-Y Growth (%) Monoclonal Antibodies, 2020–2030

Figure 14: Global Market Absolute $ Opportunity By Monoclonal Antibodies, 2020–2030

Figure 15: Global Market Value & Y-o-Y Growth (%) By Erythropoietin Stimulating Agents, 2020–2030

Figure 16: Global Market Absolute $ Opportunity By Erythropoietin Stimulating Agents, 2020–2030

Figure 17: Global Market Value & Y-o-Y Growth (%) By Opioid Analgesics, 2020–2030

Figure 18: Global Market Absolute $ Opportunity By Opioid Analgesics, 2020–2030

Figure 19: Global Market Value & Y-o-Y Growth (%) By Bisphosphonates, 2020–2030

Figure 20: Global Market Absolute $ Opportunity By Bisphosphonates, 2020–2030

Figure 21: Global Market Value & Y-o-Y Growth (%) By Granulocyte Colony Stimulating Factor, 2020–2030

Figure 22: Global Market Absolute $ Opportunity By Granulocyte Colony Stimulating Factor, 2020–2030

Figure 23: Global Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 24: Global Market Attractiveness Analysis By Indication, 2020–2030

Figure 25: Global Market Y-o-Y Growth Comparison By Indication, 2020–2030

Figure 26: Market Value Share & BPS Analysis By Indication, 2020 & 2030

Figure 27: Global Market Value & Y-o-Y Growth (%) By Lung Cancer, 2020–2030

Figure 28: Global Market Absolute $ Opportunity By Lung Cancer, 2020–2030

Figure 29: Global Market Value & Y-o-Y Growth (%) By Breast Cancer, 2020–2030

Figure 30: Global Market Absolute $ Opportunity By Breast Cancer, 2020–2030

Figure 31: Global Market Value & Y-o-Y Growth (%) By Prostate Cancer, 2020–2030

Figure 32: Global Market Absolute $ Opportunity By Prostate Cancer, 2020–2030

Figure 33: Global Market Value & Y-o-Y Growth (%) By Liver Cancer, 2020–2030

Figure 34: Global Market Absolute $ Opportunity By Liver Cancer, 2020–2030

Figure 35: Global Market Value & Y-o-Y Growth (%) By Bladder Cancer, 2020–2030

Figure 36: Global Market Absolute $ Opportunity By Bladder Cancer, 2020–2030

Figure 37: Global Market Value & Y-o-Y Growth (%) By Leukemia, 2020–2030

Figure 38: Global Market Absolute $ Opportunity By Leukemia, 2020–2030

Figure 39: Global Market Value & Y-o-Y Growth (%) By Ovarian Cancer, 2020–2030

Figure 40: Global Market Absolute $ Opportunity By Ovarian Cancer, 2020–2030

Figure 41: Global Market Value & Y-o-Y Growth (%) By Melanoma, 2020–2030

Figure 42: Global Market Absolute $ Opportunity By Melanoma, 2020–2030

Figure 43: Global Market Value & Y-o-Y Growth (%) By Other Cancer, 2020–2030

Figure 44: Global Market Absolute $ Opportunity By Other Cancer 2020–2030

Figure 45: Global Market Y-o-Y Growth Comparison By Distribution Channel, 2020–2030

Figure 46: Market Value Share & BPS Analysis By Distribution Channel, 2020 & 2030

Figure 47: Global Market Value & Y-o-Y Growth (%) By Hospital Pharmacies, 2020–2030

Figure 48: Global Market Absolute $ Opportunity By Hospital Pharmacies, 2020–2030

Figure 49: Global Market Value & Y-o-Y Growth (%) By Retail Pharmacies, 2020–2030

Figure 50: Global Market Absolute $ Opportunity By Retail Pharmacies, 2020–2030

Figure 51: Global Market Value & Y-o-Y Growth (%) By Compounding Pharmacies, 2020–2030

Figure 52: Global Market Absolute $ Opportunity By Compounding Pharmacies, 2020–2030

Figure 53: Global Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 54: Market Y-o-Y Growth Comparison By Region, 2020–2030

Figure 55: Market Value Share & BPS Analysis By Region, 2020 & 2030

Figure 56: Global Market Value & Y-o-Y Growth (%) for North America Region, 2020–2030

Figure 57: Global Market Absolute $ Opportunity for North America Region, 2020–2030

Figure 58: Global Market Value & Y-o-Y Growth (%) for Latin America Region, 2020–2030

Figure 59: Global Market Absolute $ Opportunity for Latin America Region, 2020–2030

Figure 60: Global Market Value & Y-o-Y Growth (%) for Europe Region, 2020–2030

Figure 61: Global Market Absolute $ Opportunity for Europe Region, 2020–2030

Figure 62: Global Market Value & Y-o-Y Growth (%) for Asia Pacific Region, 2020–2030

Figure 63: Global Market Absolute $ Opportunity for Asia Pacific Region, 2020–2030

Figure 64: Global Market Value & Y-o-Y Growth (%) for Middle East and Africa Region, 2020–2030

Figure 65: Global Market Absolute $ Opportunity for Middle East and Africa Region, 2020–2030

Figure 66: Global Market Attractiveness Analysis By Region, 2020–2030

Figure 67: U.S. Market Value & Y-o-Y Growth (%), 2020–2030

Figure 68: U.S. Market Absolute $ Opportunity, 2020–2030

Figure 69: Canada Market Value & Y-o-Y Growth (%), 2020–2030

Figure 70: Canada Market Absolute $ Opportunity, 2020–2030

Figure 71: North America Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 72: North America Market Attractiveness Analysis By Indication, 2020–2030

Figure 73: North America Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 74: North America Market Attractiveness Analysis By Country, 2020–2030

Figure 75: Argentina Market Value & Y-o-Y Growth (%) , 2020–2030

Figure 76: Argentina Market Absolute $ Opportunity, 2020–2030

Figure 77: Brazil Market Value & Y-o-Y Growth (%), 2020–2030

Figure 78: Brazil Market Absolute $ Opportunity, 2020–2030

Figure 79: Mexico Market Value & Y-o-Y Growth (%), 2020–2030

Figure 80: Mexico Market Absolute $ Opportunity, 2020–2030

Figure 81: Rest Of Latin America Market Value & Y-o-Y Growth (%), 2020–2030

Figure 82: Rest Of Latin America Market Absolute $ Opportunity, 2020–2030

Figure 83: Latin America Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 84: Latin America Market Attractiveness Analysis By Indication, 2020–2030

Figure 85: Latin America Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 86: Latin America Market Attractiveness Analysis By Country, 2020–2030

Figure 87: Germany Market Value & Y-o-Y Growth (%) , 2020–2030

Figure 88: Germany Market Absolute $ Opportunity, 2020–2030

Figure 89: U.K. Market Value & Y-o-Y Growth (%), 2020–2030

Figure 90: U.K. Market Absolute $ Opportunity, 2020–2030

Figure 91: France Market Value & Y-o-Y Growth (%), 2020–2030

Figure 92: France Market Absolute $ Opportunity, 2020–2030

Figure 93: Italy Market Value & Y-o-Y Growth (%), 2020–2030

Figure 94: Italy  Market Absolute $ Opportunity, 2020–2030

Figure 95: Spain Market Value & Y-o-Y Growth (%), 2020–2030

Figure 96: Spain Market Absolute $ Opportunity, 2020–2030

Figure 97: Nordic Market Value & Y-o-Y Growth (%), 2020–2030

Figure 98: Nordic Market Absolute $ Opportunity, 2020–2030

Figure 99: Russia Market Value & Y-o-Y Growth (%), 2020–2030

Figure 100: Russia Market Absolute $ Opportunity, 2020–2030

Figure 101: Rest Of Europe Market Value & Y-o-Y Growth (%), 2020–2030

Figure 102:  Rest Of Europe Market Absolute $ Opportunity, 2020–2030

Figure 103: Europe Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 104: Europe Market Attractiveness Analysis By Indication, 2020–2030

Figure 105: Europe Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 106: Europe Market Attractiveness Analysis By Country, 2020–2030

Figure 107: Greater China Market Value & Y-o-Y Growth (%), 2020–2030

Figure 108: Greater China Market Absolute $ Opportunity, 2020–2030

Figure 109: India Market Value & Y-o-Y Growth (%), 2020–2030

Figure 110: India Market Absolute $ Opportunity, 2020–2030

Figure 111: Japan Market Value & Y-o-Y Growth (%), 2020–2030

Figure 112: Japan Market Absolute $ Opportunity, 2020–2030

Figure 113: Australia and New Zealand Market Value & Y-o-Y Growth (%), 2020–2030

Figure 114: Australia and New Zealand Market Absolute $ Opportunity, 2020–2030

Figure 115: Rest of APAC Market Value & Y-o-Y Growth (%), 2020–2030

Figure 116: Rest of APAC Market Absolute $ Opportunity, 2020–2030

Figure 117: APAC Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 118: APAC Market Attractiveness Analysis By Indication, 2020–2030

Figure 119: APAC Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 120: APAC Market Attractiveness Analysis By Country, 2020–2030

Figure 121: GCC Market Value & Y-o-Y Growth (%), 2020–2030

Figure 122: GCC America Market Absolute $ Opportunity, 2020–2030

Figure 123: South Africa Market Value & Y-o-Y Growth (%), 2020–2030

Figure 124: South Africa Market Absolute $ Opportunity, 2020–2030

Figure 125: Rest Of MEA Market Value & Y-o-Y Growth (%), 2020–2030

Figure 126: Rest Of MEA Market Absolute $ Opportunity, 2020–2030

Figure 127: MEA Market Attractiveness Analysis By Drug Classes, 2020–2030

Figure 128: MEA Market Attractiveness Analysis By Indication, 2020–2030

Figure 129: MEA Market Attractiveness Analysis By Distribution Channel, 2020–2030

Figure 130: MEA Market Attractiveness Analysis By Country, 2020–2030

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Non-Operative Spine Care Market

Published : September 2019

Healthcare

Veterinary Point of Care Market

Published : March 2019

Healthcare

Dementia Care Products Market

Published : October 2017

Google translate

Cancer Supportive Care Products Market